KV Cuts Makena Price 54%, Increases Medicaid Rebates, But Is It Enough?
This article was originally published in The Pink Sheet Daily
Executive Summary
Bowing to public pressure and following an unusual intervention by FDA, KV Pharmaceuticals announced it has cut the list price of its new preterm birth prevention drug from $1,500 to $690 per injection.
You may also be interested in...
Medicaid Coverage For Gilead’s Sovaldi “Imprudent” Unless Price Reduced – Patient Group
In response to price concerns with Sovaldi, Gilead Sciences emphasized that “Medicaid, by law, receives very deep discounts, and Gilead is working with each state to complete the necessary steps to ensure a timely review and addition to the state formulary.”
Makena Pricing Prompts Multi-Pronged Appeals: FDA, FTC – Bayh-Dole?
The uproar among insurers, physicians and patient groups over the relatively high price of KV Pharmaceutical’s new injectable treatment for preventing preterm births, Makena, has elicited appeals to FDA and the Federal Trade Commission for intervention.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.